lynparza
astrazeneca ab - olaparib - neoplasmas ováricos - agentes antineoplásicos - ovario cancerlynparza está indicado como monoterapia para el:tratamiento de mantenimiento de pacientes adultos con avanzada (figo etapas iii y iv) en los genes brca1/2 mutación de la línea germinal (y/o somáticas) de alto grado epitelial de ovario, de trompa de falopio o peritoneal primario de cáncer que están en la respuesta (parcial o completa) después de la finalización de la primera línea de quimioterapia basada en platino. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 y 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. los pacientes deben haber sido tratados previamente con una antraciclina y un taxano en el (neo)adyuvante o metastásico (a menos que los pacientes no eran adecuadas para estos tratamientos (véase la sección 5. los pacientes con receptores hormonales (rh) positivo de cáncer de mama deben también han progresado en o después de antes de la terapia endocrina, o ser considerados no aptos para la terapia endocrina. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.
lynparza comprimidos recubiertos 100 mg (olaparib)
astrazeneca s.a. - olaparib - sin formulas
lynparza comprimidos recubiertos 150 mg (olaparib)
astrazeneca s.a. - olaparib - sin formulas
lynparza 50mg capsula
astrazeneca peru s.a. - olaparib; - capsula - por capsula; olaparib 50.000000 mg; - olaparib
lynparza® 150 mg
abbvie limited. - olaparib - tableta recubierta - 150 mg
lynparza® 100 mg
abbvie limited. - olaparib - tableta recubierta - 100 mg
lynparza tabletas 150 mg
astrazeneca ab suecia - olaparib 150 mg - tabletas - cada tableta contiene: olaparib 150 mg
lynparza tabletas 100 mg
astrazeneca ab suecia - olaparib 100 mg - tabletas - cada tableta contiene: olaparib 100 mg
lynparza® 150 mg tableta recubierta
astrazeneca peru s.a. - droguerÍa - tableta recubierta - por vial - - olaparib
lynparza® 100mg tableta recubierta
astrazeneca peru s.a. - droguerÍa - tableta recubierta - por vial - - olaparib